The estimated Net Worth of Robert Cohen is at least $69.1 millier dollars as of 30 June 2021. Mr. Cohen owns over 543,750 units of Zomedica Pharmaceuticals stock worth over $69,111 and over the last 4 years he sold ZOM stock worth over $0. In addition, he makes $0 as Interim Chief Executive Officer et Director at Zomedica Pharmaceuticals.
Sign up
Mr. Cohen ZOM stock SEC Form 4 insiders trading
Robert has made over 2 trades of the Zomedica Pharmaceuticals stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 543,750 units of ZOM stock worth $125,063 on 30 June 2021.
The largest trade he's ever made was exercising 3,193,750 units of Zomedica Pharmaceuticals stock on 1 June 2021 worth over $638,750. On average, Robert trades about 747,500 units every 6 days since 2020. As of 30 June 2021 he still owns at least 543,750 units of Zomedica Pharmaceuticals stock.
You can see the complete history of Mr. Cohen stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Robert Cohen biography
Robert Cohen serves as Interim Chief Executive Officer, Director of the Company. He has more than 35 years of experience developing and successfully commercializing medical and biotechnology devices. Prior to joining our company, commencing in May 2017 Mr. Cohen served as the president and chief executive officer of EmboMedics, Inc. (“EmboMedics”), a medical device company. While at EmboMedics, he led a reorganization and recapitalization of the company culminating in the successful sale of the company. Prior thereto, from November 2009 until February 2017, Mr. Cohen was a founder and President and Chief Executive Officer of Miromatrix Medical, Inc. (“Miromatrix”), a biotechnology device company. During his tenure at Miromatrix, the company developed and commercialized two products and entered into a number of partnering agreements.
How old is Robert Cohen?
Robert Cohen is 62, he's been the Interim Chief Executive Officer et Director of Zomedica Pharmaceuticals since 2020. There are 2 older and 10 younger executives at Zomedica Pharmaceuticals. The oldest executive at Zomedica Pharmaceuticals Corp. is Robert W. DiMarzo, 64, who is the Consultant.
What's Robert Cohen's mailing address?
Robert's mailing address filed with the SEC is C/O ZOMEDICA CORP., 100 PHOENIX DRIVE, SUITE 125, ANN ARBOR, MI, 48108.
Insiders trading at Zomedica Pharmaceuticals
Over the last 5 years, insiders at Zomedica Pharmaceuticals have traded over $7,040 worth of Zomedica Pharmaceuticals stock and bought 3,375,000 units worth $601,250 . The most active insiders traders include Robert Cohen, Johnny D Powers et Stephanie Morley. On average, Zomedica Pharmaceuticals executives and independent directors trade stock every 52 days with the average trade being worth of $39,452. The most recent stock trade was executed by Larry C Ii Heaton on 5 September 2024, trading 100,000 units of ZOM stock currently worth $13,000.
What does Zomedica Pharmaceuticals do?
Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company engages in the development and commercialization of TRUFORMA, a diagnostic biosensor platform for the detection of thyroid disorders in dogs and cats, and adrenal disorders in dogs. It has collaboration agreements with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and Seraph Biosciences, Inc. for development and commercialization of novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. was founded in 2015 and is headquartered in Ann Arbor, Michigan.
What does Zomedica Pharmaceuticals's logo look like?
Complete history of Mr. Cohen stock trades at Zomedica Pharmaceuticals
Zomedica Pharmaceuticals executives and stock owners
Zomedica Pharmaceuticals executives and other stock owners filed with the SEC include:
-
Dr. Stephanie Laine Morley D.V.M., DVM,
Consultant -
Bruk Herbst,
Chief Commercial Officer -
Ann Marie Cotter CPA,
CFO & Sec. -
Rodney Williams,
Independent Member -
Thomas Robitaille,
Independent Director -
Johnny Powers,
Independent Director -
Christopher MacLeod,
Independent Director -
Jane Eagleson,
Independent Director -
Christopher Wolfenberg,
Director -
Angie Moricz,
Executive Administrative Assistant -
Bruk Herbst,
Chief Commercial Officer -
Angy Guerrant,
Director of Portfolio Management -
Andrea Eberle,
Senior Marketing Manager -
William MacArthur,
Executive Member and Chief Medical Officer, Director of Research and Development -
Ann Cotter,
Chief Financial Officer, Secretary -
Robert Cohen,
Interim Chief Executive Officer, Director -
Stephanie Morley,
President, Chief Operating Officer -
Jeffrey Rowe,
Chairman of the Board -
Kristin Domanski,
VP of HR -
Nicole Westfall,
VP of Marketing -
Tony Blair,
Exec. VP of Operations -
Larry C. Heaton II,
Pres & CEO -
Robert W. DiMarzo,
Consultant -
Dr. William Carpenter MacArthur,
Consultant -
David Eaton,
VP of Marketing -
Michael Schilk,
VP of Sales -
Sean Whelan,
-
Russell Kevin Klass,
Vice President of Sales -
Rampertab Shameze,
-
James Le Bar,
Director -
Adrian Lock,
VP and General Manager -
Larry C Ii Heaton,
CEO -
Pamela Nichols,
-
Anthony K Blair,
COO -
Peter Donato,
Chief Financial Officer